Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Metabolic dysfunction-Associated Steatotic Liver Disease
Fatty Liver Disease (NAFLD and NASH)
Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Fatty Liver Disease (NAFLD and NASH)
Your liver is an incredible organ, performing more than 500 vital functions, such as filtering toxins and aiding in digestion and metabolism. Yet, liver health is often overlooked.
Each year, thousands of people are affected by liver disease. 1.5 billion people live with chronic liver disease, and 2 million lives are lost yearly. Early prevention can save many of these lives.
World Liver Day aims to spotlight the rising burden of liver diseases and the urgent need for concerted global action.
Beginning as a national effort in India, it has now become a worldwide movement, connecting people from every continent, including communities, doctors, and policymakers to promote liver health.
For Fatty Liver Disease, now more commonly known as Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), a roadmap of actions and priorities has been published and will help address this epidemic.
1) Research priorities in SLD (JHEP, 2023): https://doi.org/10.1016/j.jhep.2023.04.035
2) Action priorities in SLD (Hepatology, 2024):
Fatty liver disease is a growing health problem that often doesn’t show symptoms until it's serious. Dr. Swaranjit Bhasin, an experienced radiologist, offers three practical steps to help not just control, but possibly even reverse this condition by making some key changes to your daily habits.
In episode 10/10 of our "Liver Insights" series, we have a fabulous discussion with Jeff Lazarus, Professor of Global Health, CUNY Graduate School of Public Health and Health Policy and Research Professor at Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Today's discussion is: "Community and Support Systems: Building and leveraging support networks for enhanced coping and management."
For those living with MASLD or MASH, this discussion can be empowering. Recognizing the value of a diagnosis, utilizing support networks, and embracing lifestyle modifications with the support of loved ones can significantly impact one's quality of life and the progression of the disease.
In episode 9/10 of our "Liver Insights" series, we've brought together two top experts in liver health, Professor Shira Zelber-Sagi and Professor Jorn M. Shattenberg, to share their knowledge on how to tackle Fatty Liver Disease, also called metabolic dysfunction-associated steatotic liver disease (MASLD). Professor Zelber-Sagi, a Clinical Dietician and Epidemiologist, and Professor Schattenberg, Hepatologist an internationally recognized liver disease specialist, discuss the powerful role that changes in your daily habits can play in controlling and even reversing this liver condition.
Today's discussion is: "Strategic Action Planning for Disease Management: Enabling patients with tools and strategies for proactive disease management."
In part 8/10 of "Liver Insights: Illuminating the Path Through MASLD & MASH", and diving into our topic today "Helping patients understand and monitor their symptoms effectively." we had Dr. Maru Rinella, an international liver expert (transplant Hepatologist) from the University of Chicago, break down the stealthy nature of MASLD and MASH. She explained why these conditions often fly under the radar—many don't show symptoms until they're pretty advanced, making them tricky to catch early.
In part 7/10 of "Liver Insights: Illuminating the Path Through MASLD & MASH", we are thrilled to have as our guest, Dr. Naim Alkhouri, Chief Medical Officer (CMO), Director of the Steatotic Liver Program, at Arizona Liver Health.
This segment is "Treatment Options and Innovations: Discussion on current and emerging treatments and what patients need to know."
In a powerful Liver Insights series episode, Michael Betel from the Fatty Liver Alliance had an insightful discussion with Dr. Manal Abdelmalek, a renowned Hepatologist from the Mayo Clinic.
This episode which is 6/10 is called: "Diet and Lifestyle Adjustments: Guiding nutritional and lifestyle changes to manage and mitigate disease progression."
In part 5/10, Michael Betel , President of the Fatty Liver Alliance and Dr. Nadege Gunn, a liver expert, dive deep into living with MASLD and MASH in their chat today from the series "Liver Insights." Dr. Gunn shares her expert knowledge on how challenging these liver diseases can be and stressed the importance of keeping yourself in the loop about your health, pushing for the latest treatments, and not letting the condition define or stigmatize you.
She laid out a game plan that includes eating right, staying active, avoiding alcohol, and rallying a solid support system—family, friends, and healthcare pros who’ve got your back. It’s all about making smart choices and advocating for your health to manage these conditions effectively.
In part 4/10 of "Liver Insights: Shedding Light on MASLD & MASH," Dr. Jonathan Stine, Hepatologist at Penn State Health Center, underscores the pivotal role of patient advocacy in liver disease. He discusses how patient voices were part of what drove renaming MASLD to a more accurate term and less judgmental one, highlighting its global prevalence and progression to severe forms like MASH.
"Your Voice, Your Power as a MASLD or MASH Patient": Harnessing the power of the patient’s voice for personal and community empowerment" is an important message for patients - you have a voice and we all need to hear what you have to say!
Part 3/10 features a discussion between Michael Betel and Dr. Supriya Joshi, a passionate Hepatologist from Mississauga, Ontario, Canada, who leads the Fatty Liver Alliance Medical Advisory Committee. Dr. Joshi, also popular on Instagram, talks about addressing the stigma and fear surrounding liver disease, emphasizing the importance of removing stigma and fostering open communication between patients and physicians.
She highlights the diversity of liver diseases beyond the commonly thought-of alcohol-related liver disease and viral infections, pointing out the existence of autoimmune, genetic, and particularly metabolic liver diseases as part of the broader spectrum of metabolic disorders.
In part 2/10 of our liver health education series, Michael Betel from the Fatty Liver Alliance had a chat with Dr. Mazen Noureddin, a liver expert from Houston Methodist Hospital, about a serious health problem called fatty liver disease, focusing on two types: MASLD and MASH.
Dr. Noureddin explained that more people are getting this disease because of obesity and type 2 diabetes, which make the problem worse. He broke down the difference between MASLD, where the liver just gets fatty, and MASH, where the liver gets inflamed and could lead to cirrhosis, a very severe liver condition.
He made it clear that drinking alcohol isn't the only cause of these problems; things like diabetes, high blood pressure, being overweight, and high cholesterol play a big part too.
In this first video of 10, made for patients who already know that they have Fatty Liver Disease (MASLD) and MASH, we speak with a liver specialist, Dr. Sonal Kumar, to really understand what this disease is and how it can impact our health.
1. What is MASLD?
2. What are the risk factors and how does it progress?
3. Is it reversible?
4. Why do you need to be aware and have your liver health regularly assessed with your Physician?
Our amazing team of full and part-time volunteers are committed to helping others. We take our convictions and turn them into action. Think you would be a good fit? Get in touch for more information!
Our nonprofit charity was created to build a supportive community. Canada’s population is about 38.8M with an estimated 11.64M who may have Metabolic Dysfunction Associated Liver Disease (MASLD) (formerly NAFLD). Of those, an estimated 20% - 25% will progress to cirrhosis and suffer with Metabolic-dysfunction Associated Steatohepatitis (MASH) (formerly NASH).
We raise awareness about the risks, causes and complications of fatty liver disease and help those already diagnosed with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) by advocating for access to approved treatments and care.
Your support and contributions will enable our Registered Charity to meet our goals and your generous donations will fund our mission and purpose. Charity #79690 4704 RR0001
We will issue a tax receipt for donations of $18.00 or greater.
**Best option for us, is e-transfer to donations@fattyliver.ca
In the comment section, we need your full name and address so we can issue a tax receipt. Other payment options below.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.